Intuitive Surgical
ISRG
$378.81
+1.16%
Intuitive Surgical Inc. is a pioneer and global leader in robotic-assisted minimally invasive surgery, primarily known for its da Vinci surgical systems and the accompanying instruments, accessories, and services. The company has established a dominant market position with over 10,000 da Vinci systems installed worldwide, creating a formidable installed base and high switching costs that competitors like Medtronic are only beginning to challenge. Currently, the stock is under scrutiny as investors weigh the company's strong operational performance and long-term growth prospects against a recent sharp sell-off driven by management's decision not to raise full-year guidance after a strong Q2, alongside regulatory concerns over a surgical stapler and intensifying competition in the robotic surgery space.…
ISRG
Intuitive Surgical
$378.81
Related headlines
Investment Opinion: Should I buy ISRG Today?
Rating & Thesis: We rate ISRG a Hold, as the stock is fundamentally strong but currently faces near-term headwinds that justify a cautious stance. The consensus rating is Buy with an average target of $478.01, implying 26.2% upside, but the recent guidance disappointment and regulatory concerns create uncertainty. The core thesis is that Intuitive's dominant market position and robust growth justify a premium valuation, but the stock needs to stabilize before adding new positions.
Sign up to view all
ISRG 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Intuitive's fundamentals are strong, with accelerating revenue growth and high margins, but the valuation is stretched and the stock is in a downtrend. The recent guidance disappointment and regulatory concerns add uncertainty. The key factors suggest that the market is pricing in high expectations, and any negative surprise could lead to further downside. However, the analyst consensus and long-term growth prospects provide a floor. I would upgrade to bullish if the stock stabilizes above $400 and revenue growth remains above 20%, or if the company raises guidance. I would downgrade to bearish if revenue growth falls below 15% or if regulatory issues escalate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Intuitive Surgical's 12-month outlook, with a consensus price target around $478.01 and implied upside of +26.2% versus the current price.
Average Target
$478.01
0 analysts
Implied Upside
+26.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$324 - $685
Analyst target range
The stock is covered by 30 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.82 (where 1 is Strong Buy and 5 is Sell), indicating a bullish stance. The average price target is $478.01, which implies an upside of approximately 26.2% from the current price of $378.81, suggesting that analysts see significant recovery potential despite the recent sell-off. The target price range is wide, from a low of $324.00 to a high of $685.00, reflecting high uncertainty about the company's future performance; the low target implies a further 14.5% downside, while the high target suggests an 80.8% upside. Recent ratings have been predominantly positive, with firms like TD Cowen, RBC Capital, and B of A Securities maintaining Buy or Outperform ratings, and no downgrades in the last few months, indicating that the sell-side remains confident in the long-term story, but the wide spread in targets highlights the debate over valuation and competitive threats.
Bulls vs Bears: ISRG Investment Factors
Intuitive Surgical presents a classic growth-at-a-premium dilemma. The bull case is anchored by exceptional operational performance—22.96% revenue growth, 66% gross margins, and a dominant installed base—while the bear case centers on a rich valuation (70.8x trailing P/E) and recent negative catalysts like guidance disappointment and regulatory concerns. Currently, the bearish momentum is stronger in the short term, as evidenced by the stock's 19% annual decline and 44% max drawdown. However, the long-term fundamentals remain intact, and the key tension is whether the market's growth expectations (implied by the forward P/E of 31.4x) are achievable. If revenue growth sustains above 20% and regulatory issues are resolved, the stock could re-rate higher; if growth decelerates or competition intensifies, the valuation could compress significantly. The evidence slightly favors the bulls on a 12-month horizon given analyst targets and strong fundamentals, but near-term volatility is high.
Bullish
- Robust Revenue Growth Accelerating: Q1 2026 revenue grew 22.96% YoY to $2.77B, accelerating from 11.7% YoY in Q1 2025. This indicates strong demand for instruments and services, with recurring revenue streams providing stability.
- Dominant Market Position with High Switching Costs: Over 10,000 da Vinci systems installed globally create a massive installed base. This network effect and training ecosystem make it difficult for competitors like Medtronic to displace Intuitive, ensuring long-term revenue visibility.
- Exceptional Profitability and Cash Generation: Gross margin of 66.06% and operating margin of 30.87% in Q1 2026 demonstrate pricing power and operational efficiency. Free cash flow of $808.6M in the quarter funds buybacks and R&D, with a fortress balance sheet (debt-to-equity 0.017).
- Analyst Consensus Bullish with 26% Upside: 30 analysts rate the stock a Buy with an average target of $478.01, implying 26.2% upside from $378.81. Recent ratings from TD Cowen, RBC, and BofA remain positive, with no downgrades in months.
Bearish
- Sky-High Valuation Leaves No Room for Error: Trailing P/E of 70.8x and PEG of 3.17 are far above the healthcare sector average of ~25x. Any earnings miss or growth deceleration could trigger multiple compression, as seen in the recent 44% max drawdown.
- Stock in Clear Downtrend Underperforming Market: ISRG is down 19.38% over the past year while the S&P 500 gained 20.48%. The stock sits at 62.7% of its 52-week range, with negative relative strength across all timeframes, indicating persistent selling pressure.
- Management Guidance Disappoints Market: After a strong Q2, management declined to raise full-year guidance, signaling slower growth ahead. This triggered a sharp sell-off in July, with the stock dropping from $402 to $345 in days, reflecting investor disappointment.
- Regulatory and Safety Concerns Over Stapler: The FDA flagged safety concerns over Intuitive's surgical stapler in March 2026. This could lead to recalls, reputational damage, and increased regulatory scrutiny, potentially impacting sales and margins.
ISRG Technical Analysis
ISRG is in a clear downtrend over the past year, with the stock price down 19.38% over the last 12 months, significantly underperforming the S&P 500's gain of 20.48% during the same period. The current price of $378.81 sits at approximately 62.7% of its 52-week range (between the low of $328.57 and high of $603.88), indicating that the stock is closer to its lows than its highs, reflecting persistent selling pressure and a bearish market sentiment. This positioning suggests that the market is pricing in significant negative catalysts, and the stock could be seen as a falling knife rather than a value opportunity without clear signs of stabilization.
Beta
1.46
1.46x market volatility
Max Drawdown
-44.0%
Largest decline past year
52-Week Range
$329-$604
Price range past year
Annual Return
-19.4%
Cumulative gain past year
| Period | ISRG Return | S&P 500 |
|---|---|---|
| 1m | +11.2% | +3.6% |
| 3m | -13.5% | +2.7% |
| 6m | -24.8% | +11.4% |
| 1y | -19.4% | +18.7% |
| ytd | -32.6% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ISRG Fundamental Analysis
Intuitive Surgical's revenue growth remains robust, with the most recent quarter (Q1 2026) reporting revenue of $2.77 billion, a 22.96% year-over-year increase, and a clear acceleration from the $2.25 billion reported in Q1 2025. The growth is driven by strong demand for instruments and accessories ($1.69 billion) and services ($434 million), while systems revenue of $651 million also contributes, indicating a healthy business model that benefits from recurring revenue streams. The company's profitability is solid, with a gross margin of 66.06% and an operating margin of 30.87% in Q1 2026, both reflecting efficient operations and pricing power, though gross margins have slightly compressed from the 68.04% seen in Q4 2024. Net income for Q1 2026 was $821.5 million, yielding a net margin of 29.65%, and the company has been consistently profitable with EPS of $2.31, up from $1.95 in the year-ago quarter. The balance sheet is fortress-like, with a debt-to-equity ratio of just 0.017, a current ratio of 4.87, and robust free cash flow generation of $808.6 million in Q1 2026, which comfortably funds its capital expenditures and share repurchases, though the company did spend $1.12 billion on buybacks in that quarter, impacting cash reserves.
Quarterly Revenue
$2.8B
2026-03
Revenue YoY Growth
+23.0%
YoY Comparison
Gross Margin
66.1%
Latest Quarter
Free Cash Flow
$2.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ISRG Overvalued?
Given that Intuitive Surgical is highly profitable, the P/E ratio is the most appropriate valuation metric, and the trailing P/E stands at 70.8x, while the forward P/E is 31.4x, implying that the market expects significant earnings growth, which is consistent with the company's strong revenue momentum and margin expansion. The stock trades at a substantial premium to the broader market, with a PEG ratio of 3.17, suggesting that the growth expectations are already priced in, and any disappointment could lead to multiple compression. Compared to the industry average P/E of approximately 25x (based on the S&P 500 Healthcare sector), ISRG's trailing P/E of 70.8x represents a 183% premium, which is justified by its dominant market position, high margins, and consistent double-digit revenue growth, but leaves little room for error. Historically, ISRG's P/E has ranged from roughly 49x to 85x over the past five years, and the current trailing P/E of 70.8x is near the higher end of that band, indicating that the stock is not cheap relative to its own history, and the market is pricing in optimistic expectations for continued growth and innovation.
PE
70.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 49x~85x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
49.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Intuitive's financials are robust, but the high valuation amplifies operational risks. The trailing P/E of 70.8x and PEG of 3.17 imply that investors expect sustained double-digit growth; any slowdown could lead to severe multiple compression. The company's reliance on recurring revenue from instruments and services (which grew 22.96% YoY) is a strength, but it also means that any disruption in procedure volumes—due to economic downturns, safety recalls, or competitive alternatives—could directly impact revenue. The $1.12B spent on buybacks in Q1 2026, while returning capital, also reduces cash reserves, though the current ratio of 4.87 and debt-to-equity of 0.017 provide ample liquidity. Gross margin compression from 68.04% in Q4 2024 to 66.06% in Q1 2026, though slight, indicates potential pricing pressure or product mix shifts that could erode profitability if sustained.
FAQ
The key risks are: 1) Valuation risk - the stock trades at 70.8x trailing P/E, so any growth slowdown could cause a sharp de-rating. 2) Regulatory risk - the FDA's safety concern over the stapler could lead to recalls or restrictions, impacting sales and reputation. 3) Competitive risk - Medtronic's Hugo and other entrants could erode market share over time. 4) Macro risk - with a beta of 1.46, the stock is sensitive to market downturns, and high interest rates could compress growth multiples. The most severe risk is a combination of these factors, which could push the stock to the 52-week low of $328.57, a 13.3% downside.
The 12-month forecast is mixed. In the bull case (30% probability), the stock could reach $478-$685, driven by strong earnings and resolution of regulatory issues. In the base case (50% probability), the stock is likely to trade around $430-$500, in line with the analyst average of $478. In the bear case (20% probability), the stock could fall to $324-$378, if growth decelerates or competition intensifies. The most likely scenario is the base case, with the stock recovering from oversold levels as the company continues to execute. The key assumption is that revenue growth remains above 15% and margins stay stable.
ISRG is overvalued relative to its own history and peers. The trailing P/E of 70.8x is near the high end of its 5-year range of 49x-85x, and it is 183% above the healthcare sector average of ~25x. The forward P/E of 31.4x implies that the market expects significant earnings growth, which is consistent with the company's 22.96% revenue growth. However, the PEG ratio of 3.17 suggests that the growth is already priced in, leaving little room for error. The stock is not undervalued, but the premium is justified by its market leadership and high margins. Investors are paying for quality and growth, and any disappointment could lead to multiple compression.
ISRG is a good buy for long-term investors who believe in the growth of robotic surgery and can tolerate volatility. The stock has a consensus Buy rating with an average target of $478, implying 26.2% upside. However, the trailing P/E of 70.8x is high, and the stock is down 19.38% over the past year, so there is significant risk. The biggest downside risk is a further decline to the 52-week low of $328.57, a 13.3% drop. For investors with a 3-5 year horizon, the company's dominant market position and 22.96% revenue growth make it an attractive holding, but it is not a value stock. A better entry point might be below $350, where the forward P/E would be more reasonable.
ISRG is more suitable for long-term investment due to its growth stage and high volatility. The company is in a growth phase with revenue growing 22.96% YoY, but the stock has a beta of 1.46, making it prone to sharp swings. Short-term trading is risky given the recent downtrend and negative catalysts. For long-term investors, the company's dominant market position, recurring revenue, and innovation pipeline provide a strong foundation for compounding growth. A minimum holding period of 3-5 years is recommended to ride out volatility and benefit from the adoption of robotic surgery. The stock does not pay a dividend, so returns depend on capital appreciation.